{"id":61833,"date":"2026-03-30T16:20:34","date_gmt":"2026-03-30T08:20:34","guid":{"rendered":"https:\/\/flcube.com\/?p=61833"},"modified":"2026-03-30T16:20:35","modified_gmt":"2026-03-30T08:20:35","slug":"huahai-pharma-and-almirall-strike-340m-monoclonal-antibody-licensing-deal-targeting-dermatology-and-beyond","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61833","title":{"rendered":"Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond"},"content":{"rendered":"\n<p><strong>Zhejiang Huahai Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600521:SHA\">SHA: 600521<\/a>) announced a strategic licensing agreement with <strong>Almirall S.A.<\/strong> (Spain), granting the Barcelona-based dermatology specialist <strong>exclusive global rights (ex-China)<\/strong> to develop and commercialize novel <strong>monoclonal antibody (mAb) drug candidates<\/strong> targeting previously undisclosed pathways with potential across <strong>medical dermatology and other indications<\/strong>. Under the deal, <strong>Huahai retains full rights in China<\/strong>, while Almirall assumes global development and commercialization responsibilities outside the country. The transaction includes <strong>up to USD 340 million<\/strong> in upfront, milestone, and tiered royalty payments.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-responsibilities\">Deal Structure &amp; Responsibilities<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Party<\/th><th>Territory<\/th><th>Responsibilities<\/th><th>Financial Terms<\/th><\/tr><\/thead><tbody><tr><td><strong>Huahai Pharma<\/strong><\/td><td>China<\/td><td>Full development &amp; commercialization rights<\/td><td>Retains 100% China profits<\/td><\/tr><tr><td><strong>Almirall<\/strong><\/td><td>Global (ex-China)<\/td><td>Development, regulatory, and commercialization<\/td><td>Pays <strong>up to $340M<\/strong>: upfront + milestones + royalties<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Huahai will leverage its <strong>innovative R&amp;D platform<\/strong> to advance candidates through <strong>clinical proof-of-concept (PoC)<\/strong> before technology transfer, de-risking early-stage discovery for Almirall.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-huahai-pharma\"><strong>For Huahai Pharma<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Monetizes early innovation<\/strong>: Converts internal R&amp;D into non-dilutive capital without sacrificing China market upside<\/li>\n\n\n\n<li><strong>Validates platform<\/strong>: First major out-licensing of mAbs from its biologics engine<\/li>\n\n\n\n<li><strong>Focus alignment<\/strong>: Maintains core business in generics and CNS while building innovative pipeline<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-almirall\"><strong>For Almirall<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline diversification<\/strong>: Expands beyond small molecules into <strong>biologics for dermatology<\/strong>\u2014a high-growth segment<\/li>\n\n\n\n<li><strong>Novel mechanisms<\/strong>: Gains access to first-in-class or best-in-class mAbs targeting <strong>undisclosed pathways<\/strong> with multi-indication potential<\/li>\n\n\n\n<li><strong>Speed to clinic<\/strong>: Benefits from Huahai\u2019s PoC-stage assets, accelerating entry into Phase II\/III<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dermatology Biologics Boom<\/strong>: Global market projected to exceed <strong>$30 billion by 2030<\/strong>, driven by psoriasis, atopic dermatitis, and hidradenitis suppurativa<\/li>\n\n\n\n<li><strong>China Innovation Emergence<\/strong>: Huahai joins a growing cohort of Chinese firms (e.g., Innovent, Zai Lab) successfully out-licensing biologics to Western partners<\/li>\n\n\n\n<li><strong>Risk-Sharing Model<\/strong>: Increasingly common structure where originator handles early R&amp;D, partner takes late-stage global execution<\/li>\n<\/ul>\n\n\n\n<p>This deal reinforces Huahai\u2019s evolution from a <strong>generic API manufacturer<\/strong> to an <strong>integrated innovator with global relevance<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-impact\">Financial Impact<\/h2>\n\n\n\n<p>While upfront payment details remain undisclosed, the <strong>$340M total potential value<\/strong> represents one of the largest biologics licensing deals by a Chinese mid-tier pharma company. Proceeds will likely fund:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Expansion of Huahai\u2019s <strong>biologics CDMO capabilities<\/strong><\/li>\n\n\n\n<li>Internal pipeline acceleration in <strong>CNS and oncology<\/strong><\/li>\n\n\n\n<li>Further investment in <strong>AI-driven antibody discovery platforms<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding development timelines, regulatory approvals, and financial realization. Actual payments depend on clinical, regulatory, and commercial milestones.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/600521_20260328_6MHS.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600521_20260328_6MHS.\"><\/object><a id=\"wp-block-file--media-5bec9690-34a9-4c7c-88c9-abc82ee6e5c4\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/600521_20260328_6MHS.pdf\">600521_20260328_6MHS<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/600521_20260328_6MHS.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-5bec9690-34a9-4c7c-88c9-abc82ee6e5c4\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced a strategic licensing agreement with Almirall S.A&#8230;.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[775,1381],"class_list":["post-61833","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-huahai-pharmaceutical","tag-sha-600521"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced a strategic licensing agreement with Almirall S.A. (Spain), granting the Barcelona-based dermatology specialist exclusive global rights (ex-China) to develop and commercialize novel monoclonal antibody (mAb) drug candidates targeting previously undisclosed pathways with potential across medical dermatology and other indications. Under the deal, Huahai retains full rights in China, while Almirall assumes global development and commercialization responsibilities outside the country. The transaction includes up to USD 340 million in upfront, milestone, and tiered royalty payments.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=61833\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond\" \/>\n<meta property=\"og:description\" content=\"Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced a strategic licensing agreement with Almirall S.A. (Spain), granting the Barcelona-based dermatology specialist exclusive global rights (ex-China) to develop and commercialize novel monoclonal antibody (mAb) drug candidates targeting previously undisclosed pathways with potential across medical dermatology and other indications. Under the deal, Huahai retains full rights in China, while Almirall assumes global development and commercialization responsibilities outside the country. The transaction includes up to USD 340 million in upfront, milestone, and tiered royalty payments.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=61833\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-30T08:20:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-30T08:20:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61833#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61833\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond\",\"datePublished\":\"2026-03-30T08:20:34+00:00\",\"dateModified\":\"2026-03-30T08:20:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61833\"},\"wordCount\":403,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Huahai Pharmaceutical\",\"SHA: 600521\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61833#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61833\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=61833\",\"name\":\"Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-30T08:20:34+00:00\",\"dateModified\":\"2026-03-30T08:20:35+00:00\",\"description\":\"Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced a strategic licensing agreement with Almirall S.A. (Spain), granting the Barcelona-based dermatology specialist exclusive global rights (ex-China) to develop and commercialize novel monoclonal antibody (mAb) drug candidates targeting previously undisclosed pathways with potential across medical dermatology and other indications. Under the deal, Huahai retains full rights in China, while Almirall assumes global development and commercialization responsibilities outside the country. The transaction includes up to USD 340 million in upfront, milestone, and tiered royalty payments.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61833#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61833\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61833#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond - Insight, China&#039;s Pharmaceutical Industry","description":"Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced a strategic licensing agreement with Almirall S.A. (Spain), granting the Barcelona-based dermatology specialist exclusive global rights (ex-China) to develop and commercialize novel monoclonal antibody (mAb) drug candidates targeting previously undisclosed pathways with potential across medical dermatology and other indications. Under the deal, Huahai retains full rights in China, while Almirall assumes global development and commercialization responsibilities outside the country. The transaction includes up to USD 340 million in upfront, milestone, and tiered royalty payments.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=61833","og_locale":"en_US","og_type":"article","og_title":"Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond","og_description":"Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced a strategic licensing agreement with Almirall S.A. (Spain), granting the Barcelona-based dermatology specialist exclusive global rights (ex-China) to develop and commercialize novel monoclonal antibody (mAb) drug candidates targeting previously undisclosed pathways with potential across medical dermatology and other indications. Under the deal, Huahai retains full rights in China, while Almirall assumes global development and commercialization responsibilities outside the country. The transaction includes up to USD 340 million in upfront, milestone, and tiered royalty payments.","og_url":"https:\/\/flcube.com\/?p=61833","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-30T08:20:34+00:00","article_modified_time":"2026-03-30T08:20:35+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=61833#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=61833"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond","datePublished":"2026-03-30T08:20:34+00:00","dateModified":"2026-03-30T08:20:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=61833"},"wordCount":403,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Huahai Pharmaceutical","SHA: 600521"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=61833#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=61833","url":"https:\/\/flcube.com\/?p=61833","name":"Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-30T08:20:34+00:00","dateModified":"2026-03-30T08:20:35+00:00","description":"Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced a strategic licensing agreement with Almirall S.A. (Spain), granting the Barcelona-based dermatology specialist exclusive global rights (ex-China) to develop and commercialize novel monoclonal antibody (mAb) drug candidates targeting previously undisclosed pathways with potential across medical dermatology and other indications. Under the deal, Huahai retains full rights in China, while Almirall assumes global development and commercialization responsibilities outside the country. The transaction includes up to USD 340 million in upfront, milestone, and tiered royalty payments.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=61833#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=61833"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=61833#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61833","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=61833"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61833\/revisions"}],"predecessor-version":[{"id":61837,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61833\/revisions\/61837"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=61833"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=61833"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=61833"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}